Deal includes Austria, Germany, and Switzerland.

SwitchGear Genomics signed an agreement under which all components of its LightSwitch Luciferase Assay System™ will be promoted and sold by BioCat in Austria, Germany, and Switzerland. SwitchGear will provide full sales, marketing, and technical support for the LightSwitch Luciferase Assay System, which was launched last month.

“The agreement furthers our effort to providing a full and cost-effective reporter assay solution using new channels,” Nathan Trinklein, Ph.D., CEO and co-founder of SwitchGear Genomics, said in a statement.

The LightSwitch system is a collection of more than 30,000 cloned regulatory elements from the human genome, including 18,000 promoters and 12,000 3’UTRs luciferase reporters. The human assay-ready GoClone™ promoters are paired with optimized LightSwitch luciferase assay reagents. The goal is to measure transcriptional activation and translational efficiency in living cells.

Previous articleLonza and California Stem Cell Introduce MotorPlate Human ESC-Derived Motor Neuron Progenitors
Next articleWalter Reed to Use DiaTech Oncology’s Assay to Study Patients’ Response to Chemotherapy